<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ec8/9282877/65108074c39f/fonc-12-782877-g002.jpg"/> </div> <div class="text-side"> <h1>Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration.</h1> <p>Treatments of trametinib and chloroquine decrease MEK/ERK signaling and melanoma cell proliferation. (A, B) Immunohistochemistry of mouse melanoma tissue sections for (A) pERK and (B) Ki-67 [brown]. (C) TUNEL staining of mouse melanoma tissue sections for apoptotic cells [brown]. Nuclei was counterstained in blue with Hematoxylin. The main images and the inserts were taken at 20X and 40X objective, respectively. Scale bars: 100 Âµm. Graphs represent average percent area of tissues stained positive of pERK, Ki-67 and TUNEL + S.E. 10 to 15 images of each treatment group were analyzed via Olympus imaging analysis system. The symbols "*" and "**" represent a p-value of less than 0.05 and 0.001 respectively.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35847840/" target="_blank">35847840</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>